New pill HRS-2129 aims to ease diabetic nerve pain

NCT ID NCT07377721

Recruiting now Symptom relief Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called HRS-2129 in 168 Chinese adults with diabetic peripheral neuropathic pain (nerve pain from diabetes). Participants will receive either HRS-2129, a placebo, or the standard drug pregabalin to see if HRS-2129 reduces pain better than placebo. The trial is early-stage (Phase 1) and focuses on safety and pain relief over 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-2129
What this could lead to: If it works, this could point toward a new treatment option for diabetic nerve pain.
What could go wrong: This is an early Phase 1 study with only 168 participants, so results may not apply broadly. The drug may not prove more effective than existing treatments or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC PERIPHERAL NEUROPATHIC PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC PERIPHERAL NEUROPATHIC PAIN

Contacts and locations

Locations

China-Japan Friendship Hospital
RECRUITING

Beijing, Beijing Municipality, 100029, China
The First Affiliated Hospital of Chongqing Medical University
RECRUITING

Chongqing, Chongqing Municipality, 400016, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.